Dr. Farina is an Executive in Residence at Canaan Partners, a venture capital firm where he assesses and advises on pharmaceutical, biotechnology and healthcare investments. He is also Managing Partner of Salient Science & Technology, LLC, a consulting firm that advises several U.S. and Chinese biotech firms on strategic and technical matters in pharmaceutical R&D. Dr. Farina currently serves as the Co-Chair and Board Member of the Connecticut United for Research Excellence (CURE) organization, and is on the Advisory Board of the University of Connecticut School of Pharmacy. He is also a member of the NIH Blueprint Neurotherapeutics Network steering committee, the Emory University DRIVE Advisory Board, and was a Founder and CEO of Developing World Cures, a nonprofit company working on neglected diseases.
Dr. Farina retired in 2008 as Senior Vice President of Development at Boehringer Ingelheim Pharmaceuticals, where he was responsible for North American development of drugs in the therapeutic areas of immunology/inflammation, virology and cardiovascular disease. During his tenure, his interdisciplinary team worked on the development and successful registration of Aptivus®, an HIV protease inhibitor, Viramune XR® for HIV, and Atrovent HFA® for COPD and emphysema. Previously, he served as Vice President of Research at the Ridgefield Center. He has also held positions as the Director of Inflammatory Diseases and Director of Biochemistry over his 28-year career with Boehringer Ingelheim (BI). Prior to joining BI, he spent six years in the Corporate Research Laboratories and Medical Products Division of Union Carbide Corporation, where he did research and development of immunodiagnostics.
Dr. Farina has a Ph.D. in Organic Chemistry from SUNY Buffalo and did postdoctoral work in Bioorganic Chemistry at Pennsylvania State University with Dr. Stephen Benkovic.